Centre for Liver Cancer, National Cancer Centre, South Korea.
Centre for Gastric Cancer, National Cancer Centre, South Korea.
Br J Surg. 2017 Jan;104(2):e145-e150. doi: 10.1002/bjs.10395. Epub 2016 Nov 23.
Skin antiseptic agents are used to prevent surgical-site infection (SSI); few trials have reported the superiority of any specific agent in clean-contaminated abdominal surgery. This RCT was designed to compare the effectiveness of chlorhexidine gluconate and povidone-iodine.
Consecutive patients who underwent clean-contaminated upper gastrointestinal or hepatobiliary-pancreatic open surgery between 2011 and 2014 were assigned randomly to either chlorhexidine gluconate or povidone-iodine. The primary endpoint was the occurrence of SSI within 30 days of surgery. Secondary endpoints included causative organisms and risk factors for SSI.
A total of 534 patients were randomized; 31 (5·8 per cent) developed an SSI. There was no difference in the overall SSI rate in the chlorhexidine gluconate and povidone-iodine groups: 15 of 267 (5·6 per cent) and 16 of 267 (6·0 per cent) respectively (P = 0·853). The most common causative organism was Enterococcus faecalis. In subgroup analysis, biliary-pancreatic surgery had a higher SSI rate (26 of 127, 20·5 per cent) than upper gastrointestinal (2 of 204, 1·0 per cent) and hepatic (3 of 203, 1·5 per cent) resection. Both age (60 years and over) and type of incision were associated with the risk of SSI.
No difference was detected between chlorhexidine gluconate and povidone-iodine antiseptics for prevention of SSI. Registration number: NCT01495117 (http://www.clinicaltrials.gov).
皮肤抗菌剂用于预防手术部位感染(SSI);很少有试验报告任何特定抗菌剂在清洁污染的腹部手术中的优越性。本 RCT 旨在比较葡萄糖酸氯己定和聚维酮碘的有效性。
2011 年至 2014 年间连续接受清洁污染的上消化道或肝胆胰开放手术的患者被随机分配至葡萄糖酸氯己定或聚维酮碘组。主要终点是术后 30 天内发生 SSI。次要终点包括 SSI 的致病微生物和危险因素。
共随机分配了 534 例患者;31 例(5.8%)发生 SSI。葡萄糖酸氯己定和聚维酮碘组的总 SSI 发生率无差异:267 例中的 15 例(5.6%)和 267 例中的 16 例(6.0%)(P=0.853)。最常见的致病微生物是粪肠球菌。亚组分析显示,肝胆胰手术的 SSI 发生率(127 例中的 26 例,20.5%)高于上消化道(204 例中的 2 例,1.0%)和肝切除术(203 例中的 3 例,1.5%)。年龄(60 岁及以上)和切口类型均与 SSI 的风险相关。
葡萄糖酸氯己定和聚维酮碘抗菌剂预防 SSI 无差异。注册号:NCT01495117(http://www.clinicaltrials.gov)。